Provided by Tiger Trade Technology Pte. Ltd.

Cogent

9.17
-0.8200-8.21%
Post-market: 9.290.1200+1.31%19:59 EDT
Volume:1.86M
Turnover:17.55M
Market Cap:469.65M
PE:-9.73
High:10.16
Open:10.09
Low:9.16
Close:9.99
52wk High:45.69
52wk Low:9.00
Shares:51.22M
Float Shares:45.32M
Volume Ratio:1.00
T/O Rate:4.10%
Dividend:1.08
Dividend Rate:11.72%
EPS(TTM):-0.9421
EPS(LYR):-3.8009
ROE:-721.50%
ROA:-1.24%
PB:-13.76
PE(LYR):-2.41

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

Earning Preview: Cogent Communications Holdings, Inc. revenue is expected to decrease by 3.60%, and institutional views are cautious

Earnings Agent
·
Apr 27

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
Apr 21

A Look At Cogent Communications Holdings’s Valuation After Its Recent Share Price Rebound

Simply Wall St.
·
Apr 20

Cogent Communications Weighs Liquidity Risks Against Valuation Discount

Simply Wall St.
·
Apr 19

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

GlobeNewswire
·
Apr 17

Cogent to host first-quarter earnings call May 4

Reuters
·
Apr 15

Cogent Communications to See 'Soft' Q1, 'Strong Rebound' in H2, Oppenheimer Says

MT Newswires Live
·
Apr 08

Cogent Biosciences submits bezuclastinib new drug application to the FDA

TIPRANKS
·
Apr 01

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

GlobeNewswire
·
Apr 01

Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers

TIPRANKS
·
Mar 28

Cogent Communications Holdings Inc. Announces Annual Stockholders Meeting

Reuters
·
Mar 21

Cogent Communications Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Mar 18

Cogent price target lowered to $22 from $23 at RBC Capital

TIPRANKS
·
Mar 18

RBC Lowers Price Target on Cogent Communications Holdings to $22 From $23, Keeps Sector Perform Rating

MT Newswires Live
·
Mar 18

Cogent Comms (CCOI) Gets a Hold from RBC Capital

TIPRANKS
·
Mar 18

Cogent Biosciences Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 17

Cogent Biosciences assumed with a Buy at Jefferies

TIPRANKS
·
Mar 16

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

GlobeNewswire
·
Mar 16

Cogent CEO Dave Schaeffer to present at New Street x BCG Global Connectivity Leaders Conference

Reuters
·
Mar 13